"Neoplasm Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Descriptor ID |
D009363
|
MeSH Number(s) |
D12.776.624
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Proteins".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Proteins".
This graph shows the total number of publications written about "Neoplasm Proteins" by people in this website by year, and whether "Neoplasm Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
1999 | 2 | 0 | 2 |
2000 | 2 | 0 | 2 |
2002 | 1 | 0 | 1 |
2003 | 3 | 0 | 3 |
2004 | 1 | 0 | 1 |
2005 | 0 | 2 | 2 |
2006 | 2 | 4 | 6 |
2007 | 4 | 0 | 4 |
2008 | 2 | 1 | 3 |
2009 | 4 | 1 | 5 |
2011 | 1 | 1 | 2 |
2012 | 2 | 0 | 2 |
2013 | 1 | 0 | 1 |
2014 | 2 | 1 | 3 |
2015 | 2 | 2 | 4 |
2016 | 1 | 1 | 2 |
2017 | 4 | 0 | 4 |
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 3 | 0 | 3 |
2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Proteins" by people in Profiles.
-
Bi-allelic loss-of-function variants in BCAS3 cause a syndromic neurodevelopmental disorder. Am J Hum Genet. 2021 06 03; 108(6):1069-1082.
-
Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood. 2021 04 29; 137(17):2347-2359.
-
Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia. Am J Hematol. 2021 01; 96(1):E15-E17.
-
CASC3 promotes transcriptome-wide activation of nonsense-mediated decay by the exon junction complex. Nucleic Acids Res. 2020 09 04; 48(15):8626-8644.
-
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Invest. 2020 08 03; 130(8):4266-4281.
-
Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D. Strahlenther Onkol. 2019 Sep; 195(9):771-779.
-
The homeobox transcription factor HB9 induces senescence and blocks differentiation in hematopoietic stem and progenitor cells. Haematologica. 2019 01; 104(1):35-46.
-
A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. Int J Mol Sci. 2017 Aug 31; 18(9).
-
High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy. Horm Metab Res. 2017 Aug; 49(8):595-603.
-
Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 2017 Apr; 173(4):1017-1037.